302 related articles for article (PubMed ID: 33905554)
21. Reversal of docetaxel resistance in prostate cancer by Notch signaling inhibition.
Qiu S; Deng L; Bao Y; Jin K; Tu X; Li J; Liao X; Liu Z; Yang L; Wei Q
Anticancer Drugs; 2018 Oct; 29(9):871-879. PubMed ID: 29944470
[TBL] [Abstract][Full Text] [Related]
22. Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer.
Hoang B; Ernsting MJ; Tang WS; Bteich J; Undzys E; Kiyota T; Li SD
Cancer Lett; 2017 Dec; 410():169-179. PubMed ID: 28965854
[TBL] [Abstract][Full Text] [Related]
23. Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel.
Desarnaud F; Geck P; Parkin C; Carpinito G; Makarovskiy AN
Cancer Biol Ther; 2011 Jan; 11(2):204-12. PubMed ID: 21057205
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147.
Hao J; Madigan MC; Khatri A; Power CA; Hung TT; Beretov J; Chang L; Xiao W; Cozzi PJ; Graham PH; Kearsley JH; Li Y
PLoS One; 2012; 7(8):e40716. PubMed ID: 22870202
[TBL] [Abstract][Full Text] [Related]
25. Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia.
Nomura T; Yamasaki M; Hirai K; Inoue T; Sato R; Matsuura K; Moriyama M; Sato F; Mimata H
Mol Cancer; 2013 Apr; 12():27. PubMed ID: 23566222
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
Kim JH; Kim WS; Park C
BMC Cancer; 2019 Oct; 19(1):936. PubMed ID: 31601188
[TBL] [Abstract][Full Text] [Related]
27. Extracellular vesicles derived from glioblastoma promote proliferation and migration of neural progenitor cells via PI3K-Akt pathway.
Pan J; Sheng S; Ye L; Xu X; Ma Y; Feng X; Qiu L; Fan Z; Wang Y; Xia X; Zheng JC
Cell Commun Signal; 2022 Jan; 20(1):7. PubMed ID: 35022057
[TBL] [Abstract][Full Text] [Related]
28. Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer.
Yadav SS; Li J; Stockert JA; O'Connor J; Herzog B; Elaiho C; Galsky MD; Tewari AK; Yadav KK
Oncotarget; 2016 Nov; 7(46):76181-76196. PubMed ID: 27783994
[TBL] [Abstract][Full Text] [Related]
29. Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer.
Keresztes D; Csizmarik A; Nagy N; Módos O; Fazekas T; Bracht T; Sitek B; Witzke K; Puhr M; Sevcenco S; Kramer G; Shariat S; Küronya Z; Takács L; Tornyi I; Lázár J; Hadaschik B; Lászik A; Szűcs M; Nyirády P; Szarvas T
J Cell Mol Med; 2022 Feb; 26(4):1332-1337. PubMed ID: 34970839
[TBL] [Abstract][Full Text] [Related]
30. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
[TBL] [Abstract][Full Text] [Related]
31. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
32. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
Kosaka T; Hongo H; Oya M
BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
[TBL] [Abstract][Full Text] [Related]
33. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
[TBL] [Abstract][Full Text] [Related]
34. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer.
Gentile E; Hahn AW; Song JH; Hoang A; Shepherd PDA; Ramachandran S; Navone NM; Efstathiou E; Titus M; Corn PG; Lin SH; Logothetis CJ; Panaretakis T
Cancer Res Commun; 2023 Dec; 3(12):2531-2543. PubMed ID: 37930121
[TBL] [Abstract][Full Text] [Related]
35. microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73.
Gao Q; Zheng J
Biomed Pharmacother; 2018 Jan; 97():528-534. PubMed ID: 29091904
[TBL] [Abstract][Full Text] [Related]
36. Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel.
Zhou Y; Yang J; Zhang R; Kopeček J
Eur J Pharm Biopharm; 2015 Jan; 89():107-15. PubMed ID: 25481033
[TBL] [Abstract][Full Text] [Related]
37. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
[TBL] [Abstract][Full Text] [Related]
38. The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines.
O'Connell K; Prencipe M; O'Neill A; Corcoran C; Rani S; Henry M; Dowling P; Meleady P; O'Driscoll L; Watson W; O'Connor R
Proteomics; 2012 Jul; 12(13):2115-26. PubMed ID: 22623417
[TBL] [Abstract][Full Text] [Related]
39. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.
O'Neill AJ; Prencipe M; Dowling C; Fan Y; Mulrane L; Gallagher WM; O'Connor D; O'Connor R; Devery A; Corcoran C; Rani S; O'Driscoll L; Fitzpatrick JM; Watson RW
Mol Cancer; 2011 Oct; 10():126. PubMed ID: 21982118
[TBL] [Abstract][Full Text] [Related]
40. The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.
Liu Z; Zhu G; Getzenberg RH; Veltri RW
J Cell Biochem; 2015 Jul; 116(7):1341-9. PubMed ID: 25640606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]